ATP6V0D2

Across TCGA pan-cancer cohorts, ATP6V0D2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of ATP6V0D2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ATP6V0D2 RNA is repressed in tumor relative to normal tissue. In most cancer types ATP6V0D2 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and COAD are the cancer types where ATP6V0D2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP6V0D2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	−6.049	<.001	12	view →
KIRP	Male	II,III,IV	−6.058	<.001	11	view →
COAD	Female	III,IV	−2.028	<.001	11	view →
HNSC	All	All	+0.527	.001	10	view →
LIHC	All	All	+0.411	<.001	8	view →
STAD	Male	All	+0.881	<.001	7	view →
BLCA	All	III,IV	+0.650	.002	7	view →
BRCA	All	III,IV	+1.152	<.001	6	view →
KICH	Female	II,III,IV	+2.142	<.001	5	view →
READ	All	All	−1.357	.001	5	view →
LUSC	Male	II,III,IV	−1.328	<.001	5	view →
UCEC	All	All	+0.427	.009	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

ATP6V0D2–KIRC

Open the KIRC breakdown →